Emergent BioSolutions, Inc. (EBS)
6.33
-0.04
(-0.63%)
USD |
NYSE |
Oct 02, 16:00
6.335
0.00 (0.00%)
Pre-Market: 20:00
Emergent BioSolutions Gross Profit Margin (Quarterly) : 51.22% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 51.22% |
| March 31, 2026 | 43.31% |
| December 31, 2025 | 31.34% |
| September 30, 2025 | 55.86% |
| June 30, 2025 | 40.81% |
| March 31, 2025 | 52.43% |
| December 31, 2024 | 30.82% |
| September 30, 2024 | 54.42% |
| June 30, 2024 | -21.40% |
| March 31, 2024 | 46.40% |
| December 31, 2023 | 27.04% |
| September 30, 2023 | 33.05% |
| June 30, 2023 | 38.83% |
| March 31, 2023 | -4.81% |
| December 31, 2022 | 28.30% |
| September 30, 2022 | 32.81% |
| June 30, 2022 | 24.27% |
| March 31, 2022 | 44.75% |
| December 31, 2021 | 68.67% |
| September 30, 2021 | 29.48% |
| June 30, 2021 | 38.89% |
| March 31, 2021 | 66.71% |
| December 31, 2020 | 68.63% |
| September 30, 2020 | 57.42% |
| June 30, 2020 | 63.31% |
| Date | Value |
|---|---|
| March 31, 2020 | 52.36% |
| December 31, 2019 | 62.49% |
| September 30, 2019 | 60.65% |
| June 30, 2019 | 52.51% |
| March 31, 2019 | 44.23% |
| December 31, 2018 | 53.71% |
| September 30, 2018 | 57.97% |
| June 30, 2018 | 59.81% |
| March 31, 2018 | 51.57% |
| December 31, 2017 | 67.09% |
| September 30, 2017 | 70.83% |
| June 30, 2017 | 65.87% |
| March 31, 2017 | 60.53% |
| December 31, 2016 | 66.78% |
| September 30, 2016 | 72.55% |
| June 30, 2016 | 67.71% |
| March 31, 2016 | 76.69% |
| December 31, 2015 | 72.78% |
| September 30, 2015 | 76.55% |
| June 30, 2015 | 78.38% |
| March 31, 2015 | 71.79% |
| December 31, 2014 | 78.05% |
| September 30, 2014 | 76.50% |
| June 30, 2014 | 68.72% |
| March 31, 2014 | 64.74% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Exelixis, Inc. | 96.71% |
| Capricor Therapeutics, Inc. | -- |
| ADMA Biologics, Inc. | 69.31% |
| Akebia Therapeutics, Inc. | 77.59% |
| Arcutis Biotherapeutics, Inc. | 91.58% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -35.28% |
| Return on Assets | -13.30% |
| Return on Invested Capital | -15.62% |
| Profit Margin (Quarterly) | -76.91% |
| Operating Margin (Quarterly) | 28.25% |
| Return on Net Operating Assets | -16.25% |